Repare Therapeutics Inc Stock News
$1.25
3.10%
today
Nasdaq,
Dec 30, 10:00 pm CET
Repare Therapeutics Inc Stock News
Neutral
Business Wire
●
18 days ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Ph1 Gynecologic Expansion Clinical Trial.
Neutral
Business Wire
●
20 days ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial.
Neutral
Business Wire
●
about 2 months ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib.
Neutral
Business Wire
●
about 2 months ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results.
Neutral
Business Wire
●
2 months ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial.
Neutral
Business Wire
●
3 months ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor.
Neutral
Business Wire
●
3 months ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting.
Neutral
Business Wire
●
3 months ago
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
